Overview

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Phase 3 study to Evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650.
Phase:
Phase 3
Details
Lead Sponsor:
Intarcia Therapeutics
Treatments:
Exenatide